JP2023113639A5 - - Google Patents
Info
- Publication number
- JP2023113639A5 JP2023113639A5 JP2023077334A JP2023077334A JP2023113639A5 JP 2023113639 A5 JP2023113639 A5 JP 2023113639A5 JP 2023077334 A JP2023077334 A JP 2023077334A JP 2023077334 A JP2023077334 A JP 2023077334A JP 2023113639 A5 JP2023113639 A5 JP 2023113639A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- stereoisomer
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508327P | 2017-05-18 | 2017-05-18 | |
| US62/508,327 | 2017-05-18 | ||
| PCT/US2018/031910 WO2018213082A1 (en) | 2017-05-18 | 2018-05-09 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| JP2019563612A JP7728636B2 (ja) | 2017-05-18 | 2018-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563612A Division JP7728636B2 (ja) | 2017-05-18 | 2018-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023113639A JP2023113639A (ja) | 2023-08-16 |
| JP2023113639A5 true JP2023113639A5 (https=) | 2025-10-30 |
| JP7843731B2 JP7843731B2 (ja) | 2026-04-10 |
Family
ID=62245504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563612A Active JP7728636B2 (ja) | 2017-05-18 | 2018-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
| JP2023077334A Active JP7843731B2 (ja) | 2017-05-18 | 2023-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563612A Active JP7728636B2 (ja) | 2017-05-18 | 2018-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180334426A1 (https=) |
| EP (1) | EP3625209A1 (https=) |
| JP (2) | JP7728636B2 (https=) |
| KR (2) | KR20240150809A (https=) |
| CN (1) | CN111065622A (https=) |
| AU (1) | AU2018269568B2 (https=) |
| BR (1) | BR112019023990A2 (https=) |
| CA (2) | CA3063872A1 (https=) |
| CL (2) | CL2019003270A1 (https=) |
| CO (1) | CO2019014286A2 (https=) |
| EA (1) | EA201900562A1 (https=) |
| IL (1) | IL270595B2 (https=) |
| MA (1) | MA47392B1 (https=) |
| MX (1) | MX2019013693A (https=) |
| PH (1) | PH12019502576A1 (https=) |
| WO (1) | WO2018213082A1 (https=) |
| ZA (1) | ZA201907599B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| WO2018213082A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| CN112004557B (zh) | 2018-01-08 | 2024-07-30 | 里珍纳龙药品有限公司 | 类固醇类化合物及其抗体偶联物 |
| CN112533951A (zh) | 2018-05-09 | 2021-03-19 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| MA53455B1 (fr) | 2018-11-20 | 2022-11-30 | Regeneron Pharma | Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr |
| EP3908323A2 (en) * | 2019-01-08 | 2021-11-17 | Regeneron Pharmaceuticals, Inc. | Traceless linkers and protein-conjugates thereof |
| IL319200A (en) | 2020-04-16 | 2025-04-01 | Regeneron Pharma | Antibody-drug conjugates prepared using Diels-Alder compression methods |
| WO2021260232A1 (en) * | 2020-06-26 | 2021-12-30 | Synaffix B.V. | Methods for the preparation of linker payload constructs |
| KR20240038138A (ko) * | 2020-07-13 | 2024-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
| CA3198294A1 (en) | 2020-11-10 | 2022-05-19 | Thomas Nittoli | Selenium antibody conjugates |
| CN112661783B (zh) * | 2020-12-28 | 2022-06-07 | 中国林业科学研究院林产化学工业研究所 | 一种硅氧烷二元松香基苯并环丁烯单体及其制备方法和应用 |
| CN115006390B (zh) * | 2022-06-27 | 2024-04-19 | 国药集团动物保健股份有限公司 | 一种病毒减毒制剂、其制备方法以及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| WO2001041704A2 (en) * | 1999-12-13 | 2001-06-14 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US6908934B2 (en) * | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| EP1758651A2 (en) | 2004-06-24 | 2007-03-07 | Galapagos N.V. | Lxr agonists to promote bone homeostasis |
| US7238791B1 (en) * | 2005-12-16 | 2007-07-03 | Roche Diagnostics Operations, Inc. | 6-monoacetylmorphine derivatives useful in immunoassay |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US8993628B2 (en) | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| CN105399831A (zh) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| FI2911699T4 (fi) | 2012-10-23 | 2025-12-09 | Synaffix Bv | Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi |
| EP3057991B8 (en) * | 2013-10-15 | 2019-09-04 | The Scripps Research Institute | Chimeric antigen receptor t cell switches and uses thereof |
| FI3166638T3 (fi) | 2014-06-13 | 2025-09-17 | Glykos Finland Oy | Hyötykuorma-polymeeri-proteiini konjugaatteja |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US20160324981A1 (en) | 2015-05-08 | 2016-11-10 | The California Institute For Biomedical Research | Liver x receptor agonists and uses thereof |
| WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| WO2018213082A1 (en) * | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| CN112533951A (zh) * | 2018-05-09 | 2021-03-19 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
-
2018
- 2018-05-09 WO PCT/US2018/031910 patent/WO2018213082A1/en not_active Ceased
- 2018-05-09 EP EP18727582.1A patent/EP3625209A1/en active Pending
- 2018-05-09 MX MX2019013693A patent/MX2019013693A/es unknown
- 2018-05-09 CA CA3063872A patent/CA3063872A1/en active Pending
- 2018-05-09 KR KR1020247032445A patent/KR20240150809A/ko active Pending
- 2018-05-09 IL IL270595A patent/IL270595B2/en unknown
- 2018-05-09 MA MA47392A patent/MA47392B1/fr unknown
- 2018-05-09 JP JP2019563612A patent/JP7728636B2/ja active Active
- 2018-05-09 EA EA201900562A patent/EA201900562A1/ru unknown
- 2018-05-09 US US15/975,654 patent/US20180334426A1/en not_active Abandoned
- 2018-05-09 CN CN201880047919.2A patent/CN111065622A/zh active Pending
- 2018-05-09 BR BR112019023990-1A patent/BR112019023990A2/pt unknown
- 2018-05-09 AU AU2018269568A patent/AU2018269568B2/en active Active
- 2018-05-09 CA CA3247217A patent/CA3247217A1/en active Pending
- 2018-05-09 KR KR1020197036866A patent/KR102713173B1/ko active Active
-
2019
- 2019-11-14 CL CL2019003270A patent/CL2019003270A1/es unknown
- 2019-11-15 ZA ZA2019/07599A patent/ZA201907599B/en unknown
- 2019-11-18 PH PH12019502576A patent/PH12019502576A1/en unknown
- 2019-12-17 CO CONC2019/0014286A patent/CO2019014286A2/es unknown
-
2021
- 2021-10-05 US US17/494,762 patent/US12338199B2/en active Active
-
2023
- 2023-05-09 JP JP2023077334A patent/JP7843731B2/ja active Active
-
2024
- 2024-07-18 CL CL2024002173A patent/CL2024002173A1/es unknown
-
2025
- 2025-05-13 US US19/207,190 patent/US20250270163A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023113639A5 (https=) | ||
| JP2023179713A5 (https=) | ||
| JP2019031565A5 (https=) | ||
| RU2010130993A (ru) | Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления | |
| JP2012522513A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| JP2024059609A5 (https=) | ||
| JP2025131777A5 (https=) | ||
| JP2023081303A5 (https=) | ||
| CN111936169A (zh) | 喜树碱肽缀合物 | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| JP2023123726A5 (https=) | ||
| JP2017514905A5 (https=) | ||
| CN110167355A (zh) | 多药抗体药物偶联物 | |
| JP2020526584A5 (https=) | ||
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| WO2009100194A2 (en) | Camptothecin-binding moiety conjugates | |
| CA2860175A1 (en) | Camptothecin-binding moiety conjugates | |
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| IL277049B1 (en) | Conjugates of biparatopic anti-HER2 antibody and drug and methods of use | |
| JP2021515793A5 (https=) | ||
| JP2019513013A5 (https=) | ||
| JPWO2020223221A5 (https=) | ||
| JPWO2021251459A5 (https=) | ||
| JP2024020436A5 (https=) |